We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+21.1%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.86B
AUM Growth
-$150M
(-5%)
Cap. Flow
-$428M
Cap. Flow
% of AUM
-14.96%
Top 10 Holdings %
Top 10 Hldgs %
28.09%
Holding
113
New
30
Increased
18
Reduced
43
Closed
20
Top Buys
| 1 |
GE HealthCare
GEHC
|
+$83.4M |
| 2 |
AbbVie
ABBV
|
+$76M |
| 3 |
Eli Lilly
LLY
|
+$55.8M |
| 4 |
Pfizer
PFE
|
+$43.5M |
| 5 |
APLS
Apellis Pharmaceuticals
APLS
|
+$40.4M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$72.7M |
| 2 |
Surgery Partners
SGRY
|
+$68.7M |
| 3 |
AKRO
Akero Therapeutics
AKRO
|
+$65.2M |
| 4 |
Merck
MRK
|
+$63.8M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
+$56.9M |
Sector Composition
| 1 | Healthcare | 99.98% |
| 2 | Technology | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Becton Dickinson
BDX
$42.7B
| $105M | 3.67% |
398,050
+110,050
| +38% | +$27.9M |
|
|
KRTX
2
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $95.9M | 3.35% |
442,200
+38,400
| +10% | +$8.23M |
|
3
Jazz Pharmaceuticals
JAZZ
$15B
| $87.1M | 3.04% |
702,778
+24,878
| +4% | +$3.35M |
|
|
4
GE HealthCare
GEHC
$28.7B
| $84.9M | 2.97% |
+1,045,400
| New | +$83.4M |
|
5
Tenet Healthcare
THC
$16.6B
| $80.6M | 2.82% |
990,500
-481,500
| -33% | -$34.3M |
|
6
argenx
ARGX
$54B
| $71.8M | 2.51% |
184,300
-96,400
| -34% | -$37.9M |
|
7
IDEAYA Biosciences
IDYA
$3.54B
| $70.2M | 2.45% |
2,985,700
-687,700
| -19% | -$14.1M |
|
|
8
Surgery Partners
SGRY
$2.08B
| $70M | 2.44% |
1,555,000
-1,800,900
| -54% | -$68.7M |
|
|
9
AbbVie
ABBV
$431B
| $69.8M | 2.44% |
+518,400
| New | +$76M |
|
10
Arvinas
ARVN
$534M
| $68.8M | 2.4% |
2,773,189
-1,500,711
| -35% | -$38.6M |
|
11
Zentalis Pharmaceuticals
ZNTL
$340M
| $65.8M | 2.3% |
2,334,000
-595,300
| -20% | -$14.3M |
|
12
Neurocrine Biosciences
NBIX
$17.3B
| $62.7M | 2.19% |
665,316
-150,384
| -18% | -$14.7M |
|
|
13
Eli Lilly
LLY
$1.03T
| $62.4M | 2.18% |
+133,000
| New | +$55.8M |
|
14
Syndax Pharmaceuticals
SNDX
$2.08B
| $60.1M | 2.1% |
2,872,000
-993,300
| -26% | -$20.7M |
|
15
Universal Health Services
UHS
$8.96B
| $58.4M | 2.04% |
370,100
-299,900
| -45% | -$41.8M |
|
16
Bio-Rad Laboratories Class A
BIO
$7.91B
| $57.9M | 2.02% |
152,600
-68,900
| -31% | -$28M |
|
17
Cencora
COR
$57.7B
| $57.7M | 2.02% |
300,000
+173,400
| +137% | +$30M |
|
18
Pacific Biosciences
PACB
$475M
| $57.7M | 2.01% |
4,337,400
+524,800
| +14% | +$6.38M |
|
19
Legend Biotech
LEGN
$4.46B
| $55.1M | 1.93% |
798,900
-321,600
| -29% | -$21M |
|
20
Biogen
BIIB
$29.1B
| $49.6M | 1.73% |
174,000
+45,200
| +35% | +$13.5M |
|
|
AKRO
21
DELISTED
Akero Therapeutics
AKRO
| $47.9M | 1.67% |
1,025,000
-1,422,000
| -58% | -$65.2M |
|
|
CVAC
22
DELISTED
CureVac
CVAC
| $44.8M | 1.56% |
4,300,000
+750,000
| +21% | +$6.71M |
|
23
Acadia Healthcare
ACHC
$2.97B
| $43.8M | 1.53% |
550,000
-615,300
| -53% | -$44.5M |
|
24
Vaxcyte
PCVX
$8.19B
| $43.7M | 1.53% |
875,000
+365,000
| +72% | +$17.3M |
|
25
McKesson
MCK
$93.2B
| $43.2M | 1.51% |
+101,200
| New | +$38.9M |
|
Similar funds
NM
LM
IF
PWAM
CM
LJAC
PO
SH